Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 7/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.44 |
| ▸ | Q9HBH1 | 1/20 | 0.41 | |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944471 | 1.00 | PLA2G2C (0.54) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| SCHEMBL14090829 | 1.00 | PLA2G2C (0.54) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| SCHEMBL4531941 | 0.88 | PLA2G2C (0.44) | PLA2G2CPLA2G2AGPR84GNPAT | |
| SCHEMBL6547737 | 0.86 | PLA2G2C (0.62) | PLA2G2CPLA2G2ACA2 | |
| SCHEMBL5178306 | 0.84 | PLA2G2C (0.44) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| SCHEMBL4205637 | 0.84 | PLA2G2C (0.44) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| SCHEMBL4192229 | 0.83 | PLA2G2C (0.43) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| Hydrochloric Acid SCHEMBL4199756 | 0.83 | PLA2G2C (0.43) | PLA2G2CPLA2G2AGPR84PDFPLA2G10 | |
| SCHEMBL1526830 | 0.83 | GNPAT (0.42) | PLA2G2CGNPAT | |
| SCHEMBL27493484 | 0.83 | GNPAT (0.42) | PLA2G2CGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | PLA2G2C 1336/4885PLA2G2A 4033/4885GPR84 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.